Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen ...
Do SERMs Favorably Impact Clinical Markers of Cardiovascular Risk? In women, menopause is accompanied by clear changes in serum lipoproteins, [30] and plasma lipoprotein levels are clear predictors of ...
A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...
Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...
SAN DIEGO and GAINESVILLE, Ga., May 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (SCTL) (“Societal CDMO”; Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to ...
(RTTNews) - Athira Pharma, Inc. (ATHA) has acquired exclusive global rights to Lasofoxifene, a selective estrogen receptor modulator now in pivotal Phase 3 trial for ESR1-mutant metastatic breast ...
Dr Vidula and Dr Lu describe how selective estrogen receptor degraders (SERDs) differ in their mechanism of action from other therapies for ER+/HER2– metastatic breast cancer and how newer SERDs ...
Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results